A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
NCT06921837
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
122
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastric Cancer Adenocarcinoma Metastatic
Gastroesophageal Adenocarcinoma
Interventions
DRUG:
BDC-4182
Sponsor
Bolt Biotherapeutics, Inc.